Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change $ Change
grade F $2.85 1.79% 0.05
ACRX closed up 1.79 percent on Friday, January 13, 2017, on 1.18 times normal volume. It ran into resistance at its 50 day moving average.
Track This Stock
Watchlist Portfolio
Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical ACRX trend table...

Date Alert Name Type % Chg
Jan 13 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 13 Bollinger Band Squeeze Range Contraction 0.00%
Jan 13 50 DMA Resistance Bearish 0.00%
Jan 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 12 Bollinger Band Squeeze Range Contraction 0.00%
Jan 11 Volume Surge Other 5.56%
Jan 11 50 DMA Resistance Bearish 5.56%
Jan 10 Doji - Bearish? Reversal 7.55%
Jan 6 New Downtrend Bearish 9.62%
Jan 5 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 7.55%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio.

AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company’s principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. In addition, the company’s product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 4.5
52 Week Low 2.4
Average Volume 235,174
200-Day Moving Average 3.2
50-Day Moving Average 2.89
20-Day Moving Average 2.73
10-Day Moving Average 2.67
Average True Range 0.18
ADX 23.13
+DI 20.99
-DI: 17.7
Chandelier Exit (Long, 3 ATRs) 2.56
Chandelier Exit (Short, 3 ATRs) 2.99
Upper Bollinger Band 2.94
Lower Bollinger Band 2.52
Percent B (%b) 0.79
Bandwidth 0.153846